Ligand Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 3/4
Ligand Pharmaceuticals CEO'su Todd Davis, Dec2022 tarihinde atandı, in görev süresi 1.92 yıldır. in toplam yıllık tazminatı $ 6.22M olup, şirket hissesi ve opsiyonları dahil olmak üzere 10.5% maaş ve 89.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.42% ine doğrudan sahiptir ve bu hisseler $ 9.44M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2 yıl ve 15 yıldır.
Anahtar bilgiler
Todd Davis
İcra Kurulu Başkanı
US$6.2m
Toplam tazminat
CEO maaş yüzdesi | 10.5% |
CEO görev süresi | 1.9yrs |
CEO sahipliği | 0.4% |
Yönetim ortalama görev süresi | 2yrs |
Yönetim Kurulu ortalama görev süresi | 15yrs |
Son yönetim güncellemeleri
Recent updates
Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies
Nov 24Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings
Oct 31Ligand Pharmaceuticals: Solid Performer Performing Solidly
Jul 29Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 18Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?
Jun 29Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%
May 23Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio
Apr 30Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar
Dec 19Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?
Jun 14We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?
May 07These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Ligand Pharmaceuticals: Struggling Along
Sep 25Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Aug 11Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Sep 30 2024 | n/a | n/a | US$45m |
Jun 30 2024 | n/a | n/a | US$42m |
Mar 31 2024 | n/a | n/a | US$96m |
Dec 31 2023 | US$6m | US$650k | US$54m |
Sep 30 2023 | n/a | n/a | US$21m |
Jun 30 2023 | n/a | n/a | US$41m |
Mar 31 2023 | n/a | n/a | US$51m |
Dec 31 2022 | US$6m | US$49k | -US$5m |
Sep 30 2022 | n/a | n/a | US$23m |
Jun 30 2022 | n/a | n/a | US$27m |
Mar 31 2022 | n/a | n/a | US$45m |
Dec 31 2021 | US$328k | n/a | US$76m |
Sep 30 2021 | n/a | n/a | US$68m |
Jun 30 2021 | n/a | n/a | US$48m |
Mar 31 2021 | n/a | n/a | US$39m |
Dec 31 2020 | US$329k | n/a | US$7m |
Sep 30 2020 | n/a | n/a | -US$16m |
Jun 30 2020 | n/a | n/a | -US$25m |
Mar 31 2020 | n/a | n/a | -US$61m |
Dec 31 2019 | US$350k | n/a | US$629m |
Sep 30 2019 | n/a | n/a | US$594m |
Jun 30 2019 | n/a | n/a | US$677m |
Mar 31 2019 | n/a | n/a | US$764m |
Dec 31 2018 | US$343k | n/a | US$143m |
Sep 30 2018 | n/a | n/a | US$179m |
Jun 30 2018 | n/a | n/a | US$120m |
Mar 31 2018 | n/a | n/a | US$53m |
Dec 31 2017 | US$283k | n/a | US$13m |
Tazminat ve Piyasa: Todd 'ın toplam tazminatı ($USD 6.22M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.50M ).
Tazminat ve Kazançlar: Todd 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Todd Davis (63 yo)
1.9yrs
Görev süresi
US$6,216,518
Tazminat
Mr. Todd C. Davis, Ph.D. is a Director at NVN Liquidation Inc. He serves as an Independent Director of Channel Therapeutics Corporation (formerly known as Chromocell Therapeutics Corporation) since January...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO & Director | 1.9yrs | US$6.22m | 0.42% $ 9.4m | |
Chief Financial Officer | 2yrs | US$2.45m | 0.13% $ 2.9m | |
Chief Legal Officer & Secretary | 2yrs | US$2.34m | 0.12% $ 2.7m | |
Senior Vice President of Investments & Business Development | no data | Veri yok | Veri yok | |
Head of Investor Relations | no data | Veri yok | Veri yok | |
Director of Corporate Development | no data | Veri yok | Veri yok | |
Senior Vice President of Biology & Scientific Affairs | 6.8yrs | Veri yok | Veri yok | |
Senior Vice President of Technical Operations & QA - Capitsol | 6.8yrs | Veri yok | Veri yok | |
Senior VP & CBO Protein Expression Business | no data | Veri yok | Veri yok | |
Senior VP of Investments & Head of Clinical Strategy | less than a year | Veri yok | Veri yok | |
Senior VP of Investment Operation | less than a year | Veri yok | Veri yok | |
CEO of Pelthos Therapeutics | less than a year | Veri yok | Veri yok |
2.0yrs
Ortalama Görev Süresi
57yo
Ortalama Yaş
Deneyimli Yönetim: LGND 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 2 yıl), bu da yeni bir ekibin varlığını gösteriyor.
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO & Director | 17.7yrs | US$6.22m | 0.42% $ 9.4m | |
Independent Chairman | 21.7yrs | US$361.70k | 0.23% $ 5.1m | |
Independent Director | 13.8yrs | US$329.20k | 0.15% $ 3.4m | |
Independent Director | 16.3yrs | US$341.70k | 0.15% $ 3.4m | |
Independent Director | 18.2yrs | US$339.20k | 0.43% $ 9.8m | |
Scientific Advisor | no data | Veri yok | Veri yok | |
Independent Director | 2.4yrs | US$346.70k | 0.022% $ 494.1k | |
Independent Director | 7.3yrs | US$336.70k | 0.030% $ 671.4k | |
Independent Director | 1.2yrs | US$467.87k | Veri yok |
15.0yrs
Ortalama Görev Süresi
63.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: LGND 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 15 yıldır).